Pharvaris N.V. (PHVS)

USD 18.5

(0.05%)

Market Cap (In USD)

999.14 Million

Revenue (In USD)

-

Net Income (In USD)

-100.87 Million

Avg. Volume

87.59 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
15.37-33.0
PE
-
EPS
-
Beta Value
-3.145
ISIN
NL00150005Y4
CUSIP
N69605108
CIK
1830487
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Berndt Axel Edvard Modig CPA, M.B.A.
Employee Count
-
Website
https://pharvaris.com
Ipo Date
2021-02-05
Details
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.